ÂÜÀòÂÒÂ×

Corey Pelletier has a strong background in health economics and outcomes research (HEOR) and has held various leadership positions in reputable pharmaceutical and biotech companies.

Corey currently serves as the Executive Director and Head of U.S. HEOR at Stemline Therapeutics since November 2022.

Before joining Stemline Therapeutics, Pelletier worked as the Head of HEOR at Phathom Pharmaceuticals from January 2021 to November 2022.

Prior to that, Pelletier was the Senior Director and U.S. HEOR CAR T Team Lead at Bristol-Myers Squibb from November 2019 to January 2021.

Corey also held roles at Celgene, serving as the Senior Director and U.S. HEOR for the Inflammation & Immunology Team Lead from January 2017 to October 2019, and as the Director and U.S. HEOR Solid Tumor Team Lead from February 2016 to December 2016.

Pelletier gained experience in global value and access at Eisai, where they worked as the Director of Global Value & Access - Oncology from December 2013 to February 2016.

Earlier in their career, Pelletier held the position of Associate Director of Global Health Economics and Market Access at Novartis Oncology from June 2011 to December 2013.

Pelletier's career in HEOR started at Kantar Health, where they worked as a Consultant from December 2006 to July 2011.

Corey Pelletier attended Deerfield Academy for high school and obtained a high school degree. Later, they pursued a Bachelor of Arts (BA) degree in Biochemistry at Vassar College. Corey then went on to pursue a PhD in Molecular Cell Biology at Washington University School of Medicine in St. Louis.